Skip to main content
Premium Trial:

Request an Annual Quote

Celera Offers Database to Israel - Newspaper Says

NEW YORK, Dec 1 - Celera has offered a subscription to its genome database to the Israeli government, the Israeli newspaper Ha’aretz reported Friday.

The company offered the database subscription to Yossi Cucik, the director general of the Israeli prime minister’s office, when he visited the United States in mid-November, the newspaper said.

The database will be made available to academic institutions and government offices in Israel, Cucik told Ha’aretz.

Cucik has arranged a meeting between Celera CEO Craig Venter and Israeli Prime Minister Ehud Barak. The newspaper implied that Venter intended to visit Israel in the near future. Celera was not immediately available for comment.

This report follows Celera’s October announcement that it had licensed its database to Israel's Weizmann Institute of Science. Typically, Celera charges academic and public-sector subscribers between $6,000 and $15,000 per scientist for access to its database .

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.